Company profile: Mythic Therapeutics
1.1 - Company Overview
Company description
- Provider of biotechnology-based cancer therapeutics, including MYTX-011, an investigational cMET-targeting antibody-drug conjugate designed to increase delivery of chemotherapy to cancer cells while reducing uptake in healthy cells; FateControl™, a platform that enhances ADC uptake in cancer cells and minimizes payload release in normal cells to improve potency and tolerability; and KisMET-01, a Phase 1 trial in NSCLC.
Products and services
- FateControl™: A cell-selective technology platform that enhances ADC uptake in cancerous cells and minimizes payload release in normal cells, improving therapeutic potency and tolerability
- MYTX-011: An investigational cMET-targeting antibody-drug conjugate (ADC) engineered to increase chemotherapy delivery to cancer cells while reducing uptake in healthy cells
- KisMET-01: A Phase 1 clinical trial evaluating safety, tolerability, pharmacokinetics, and preliminary effectiveness of MYTX-011 in patients with non-small cell lung cancer (NSCLC)
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Mythic Therapeutics
ECM Therapeutics
HQ: United States
Website
- Description: Provider of regenerative natural biomaterials, including extracellular matrix hydrogel for tissue regeneration, void filling, and as a drug carrier; matrix bound nanovesicles offering immunomodulation without suppression, administered intravenously or topically; and FDA-approved extracellular matrix-based surgical scaffolds for applications such as hernia repair and breast reconstruction.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ECM Therapeutics company profile →
QSAM Biosciences
HQ: United States
Website
- Description: Provider of nuclear medicines for the treatment of cancer and related diseases and conditions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full QSAM Biosciences company profile →
StageZero Life Sciences
HQ: Canada
Website
- Description: Provider of blood-based diagnostics for early disease detection, including ARISTOTLE, a single-sample test detecting molecular signatures of nine cancers (e.g., breast, ovarian, colorectal); ColonSentry, a gene expression blood test for early colorectal cancer without dietary restrictions or stool handling; and AVRT, a program that identifies early cancer risk factors and provides actionable lifestyle guidance.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full StageZero Life Sciences company profile →
Kiadis Pharma
HQ: The Netherlands
Website
- Description: Provider of novel biopharmaceutical treatment options focused on complications and limitations of hematopoietic stem cell transplants in blood cancer patients, with three products in clinical development addressing high-unmet medical needs of terminally ill cancer patients.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Kiadis Pharma company profile →
Salmedix
HQ: United States
Website
- Description: Provider of oncology drug development focused on hematologic malignancies (blood cancers). Primary product SDX-105 is marketed by healthcare professionals in Germany for several types of blood cancers; conducts Phase II clinical trials for SDX-105 in the U.S. and Canada.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Salmedix company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Mythic Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Mythic Therapeutics
2.2 - Growth funds investing in similar companies to Mythic Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Mythic Therapeutics
4.2 - Public trading comparable groups for Mythic Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →